Mark Feitelson

Temple University United States of America

Mark Feitelson received his Ph.D. in Microbiology and Immunology in 1979 from UCLA. He began his work with hepatitis B at Stanford University and was then recruited to the Fox Chase Cancer Center by Dr. Baruch Blumberg (Nobel laureate). He has since worked on the pathogenesis of hepatitis B. In 1991, Dr. Feitelson moved to Thomas Jefferson University where he became Professor of Pathology and Cell Biology. He also was director of a Molecular Diagnostics Lab in Microbiology. In 2007, Dr. Feitelson went to Temple University as a Professor of Biology. His work has been supported by NIH, industry, and foundations, has more than 150 publications, and 180 abstracts. He is also the CSO of SFA Therapeutics. He has 11 patents and has mentored over 130 students.

Mark Feitelson

1books edited

1chapters authored

Latest work with IntechOpen by Mark Feitelson

Hepatocellular carcinoma (HCC) is a common tumor type arising from several distinct etiologies. It is usually diagnosed late and is difficult to treat. This volume presents an overview of selected aspects of HCC pathogenesis, and research aimed at developing diagnostic biomarkers. It points to a number of putative therapeutic targets, including signal transduction pathways, metabolic and epigenetic alterations in tumor cells, the tumor microenvironment, the gut microbiome, and functions of immune effector cells. Given the multi-step nature of most cancers, including HCC, future drug development will most likely require combination therapies that will simultaneously target multiple steps in hepatocarcinogenesis.

Go to the book